Cognitive function in breast cancer survivors

Cancer Treatment and Research

Volumn 151, Issue , 2009, Pages 387-419

  Vardy, Janette ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; FLUOROURACIL; GLUCOCORTICOID; METHOTREXATE; TAMOXIFEN; THIOTEPA;

ANEMIA; ANXIETY DISORDER; BRAIN BLOOD FLOW; BRAIN OXYGEN CONSUMPTION; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CAPILLARY PERMEABILITY; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG SUBSTITUTION; FATIGUE; HUMAN; INCIDENCE; INTRADUCTAL CARCINOMA; MENTAL STRESS; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; SURVIVORS;

EID: 77953674562     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-75115-3_24     Document Type: Review

References (224)

1. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701
2. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-493
3. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210-218
4. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640-650
5. Wieneke MH, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61-66
6. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175-4183
7. Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer:Report of a Workshop. J Clin Oncol. 2004;22:2233-2239
8. Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955-969
9. Wefel JS, Lenzi R, Theriault R, et al. 'Chemobrain' in breast carcinoma?:A prologue. Cancer. 2004;101:466-475
10. Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405-412
11. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2000;19:812-820
12. Downie FP, Mar Fan HG, Houede-Tchen N, et al. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921-930
13. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer. 2002; 3(Suppl 3):S91-s99.
14. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234-248
15. Butters N, Grant I, Haxby J, et al. Assessment of AIDS-related cognitive changes:Recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol. 1990;12:963-978
16. Cummings JL, Benson DF. Subcortical dementia. Review of an emerging concept. Arch Neurol. 1984;41:874-879
17. Massman PJ, Delis DC, Butters N, et al. Are all subcortical dementias alike? Verbal learning and memory in Parkinson's and Huntington's disease patients. J Clin Exp Neuropsychol. 1990;12:729-744
18. Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685-691
19. Heaton RK, Kirson D, Velin D, RA. Grant I. and the HNRC Group: The Utility of Clinical Ratings for Detecting Cognitive Change in HIV Infection, in Grant IM, A. (ed) Neuropsychology of HIV Infection. New York: Oxford University Press, 1994, pp.188-206.
20. Heaton RK, Grant I, Butters N, et al. TheHNRC500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231-251
21. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307-319
22. Martin EM, Sullivan TS, Reed RA, et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7:20-26
23. Durvasula RS, Miller EN, Myers HF, et al. Predictors of neuropsychological performance in HIV positive women. J Clin Exp Neuropsychol. 2001;23:149-163
24. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. 3rd ed. New York: The Psychological Corporation; 1997
25. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3:215-222
26. Minisini A, Atalay G, Bottomley A, et al. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol. 2004;5:273-282
27. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med. 1974;291:127-133
28. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med. 1974;291:75-81.
29. Oxman TE, Silberfarb PM. Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry. 1980;137:1263-1265
30. Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry. 1980;137:597-601.
31. Kaasa S, Olsnes BT, Thorud E, et al. Reduced short-term neuropsychological performance in patients with nonsmall-cell lung cancer treated with cisplatin and etoposide. Antibiot Chemother. 1988;41:226-231
32. Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: Effect of previous treatment. Neurology. 1992;42:434-436
33. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995;12:231-235
34. Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med. 1983;34:35-46.
35. Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33:179-182
36. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst. 2003;95:190-197
37. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422-430
38. Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499-2507
39. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006.
40. Mar Fan H, Houé dé -Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock I.F. Fatigue, menopausal symptoms and cognitive function in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study. J Clin Oncol. 2005;23:8025-8032
41. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5:439-446
42. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function:A follow-up study in breast cancer patients. Ann Oncol. 2002;13: 1387-1397
43. Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standarddose chemotherapy: Evaluation of long-term treatment effects. Ann Oncol. 2006;17:415-423
44. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma:Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292-2299
45. Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer:A new dose-limiting toxic effect? J Natl Cancer Inst. 1998;90:182-183
46. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3(Suppl 3):S84-90.
47. Bender CM, Paraska KK, Sereika SM, et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer:A critical review. J Pain Symptom Manage. 2001;21:407-424
48. Cimprich B. Symptom management: Loss of concentration. Semin Oncol Nurs. 1995;11: 279-288
49. McAllister TW, Ahles TA, Saykin AJ, et al. Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep. 2004;6:364-371
50. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients:A review of the literature. Psychooncology. 1997;6:169-177
51. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). 2000;14:75-9;discussion 79,81-2,85.
52. Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park). 1990;4:115-22;discussion 122,126-7,130.
53. Meyers CA, Weitzner M, Byrne K, et al. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994; 12:820-826
54. Meyers CA, Weitzner MA. Neurobehavioral functioning and quality of life in patients treated for cancer of the central nervous system. Curr Opin Oncol. 1995;7:197-200.
55. Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park). 2001;15:613-8;discussion 618,621-624
56. O'Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs. 2003;19:17-24.
57. O'Shaughnessy JA. Chemotherapy-induced cognitive dysfunction:A clearer picture. Clin Breast Cancer. 2003;4(Suppl 2):S89-94.
58. Peterson LG, Popkin MK. Neuropsychiatric effects of chemotherapeutic agents for cancer. Psychosomatics. 1980;21:141-153
59. Redd WH, Silberfarb PM, Andersen BL, et al. Physiologic and psychobehavioral research in oncology. Cancer. 1991;67:813-822
60. Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003;30:749-762
61. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry. 2003;8:201-216
62. Schagen SB, Muller MJ, Boogerd W, et al. Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clin Breast Cancer. 2002;3(Suppl 3): S100-8.
63. Oxman TE, Schnurr PP, Silberfarb PM. Assessment of cognitive function in cancer patients. Hosp J. 1986;2:99-128 .
64. Silberfarb PM, Oxman TE. The effects of cancer therapies on the central nervous system. Adv Psychosom Med. 1988;18:13-25.
65. Tope DM, Ahles TA, Silberfarb PM. Psycho-oncology: Psychological well-being as one component of quality of life. Psychother Psychosom. 1993;60:129-147
66. Troy L, McFarland K, Littman-Power S, et al. Cisplatin-based therapy:A neurological and neuropsychological review. Psychooncology. 2000;9:29-39.
67. Morse R, Rodgers J, Verrill M, et al. Neuropsychological functioning following systemic treatment in women treated for breast cancer:A review. Eur J Cancer. 2003;39:2288-2297
68. Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer. 2002;3(Suppl 3): S121-7.
69. Matsuda T, Takayama T, Tashiro M, et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12:279-287
70. Raffa RB, Duong PV, Finney J, et al. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31:129-138
71. Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006;13:362-369
72. Castellon SA, Silverman DH, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat. 2005;92:199-206.
73. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies:A conceptual review of an emerging target. Br J Cancer. 2004;90: 1691-1696
74. Baumgartner K. Neurocognitive changes in cancer patients. Semin Oncol Nurs. 2004;20: 284-290
75. Paraska K, Bender CM. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncol Nurs Forum. 2003;30:473-478
76. Ahles TA. Do systemic cancer treatments affect cognitive function? Lancet Oncol. 2004; 5:270-271
77. Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer:A meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967-982
78. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer:A metaanalysis of the current literature. Brain Cogn. 2005;59:60-70.
79. Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222-2233
80. Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76-89.
81. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61-66
82. Tchen N JH, Downie F, Yi Q, Hu H, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;22(22):4175-4183
83. Mar Fan H, Vardy J, Xu W, Tannock IF. Does cognitive impairment after chemotherapy improve over time or does practice make perfect? In reply. J Clinl Oncol. 2006;24:5171-5172
84. Cimprich B, So H, Ronis DL, et al. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14:70-78
85. Shilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. Breast. 2005;14:142-150
86. Symes E, Maruff P, Ajani A, et al. Issues associated with the identification of cognitive change following coronary artery bypass grafting. Aust N Z J Psychiatry. 2000;34: 770-784
87. Ingraham L, Aiken, CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120-124
88. Bornstein R. Methodological and conceptual issues in the study of cognitive change in HIV infection, in Grant IM A. ed. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994
89. Gonzalez R, Heaton RK, Moore DJ, et al. Computerized reaction time battery versus a traditional neuropsychological battery: Detecting HIV-related impairments. J Int Neuropsychol Soc. 2003;9:64-71.
90. Vardy J. Cognitive impairment postchemotherapy. Review. American Journal of Oncology. 2004;3:568-570
91. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2005;1-5.
92. Taylor MJ, Heaton RK. Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc. 2001;7:867-874
93. Fletcher RH, Fletcher SW, Wagner EH. Responsiveness, In: Satterfield T ed. Clinical epidemiology: the essentials 2nd ed. Baltimore: Williams & Wilkins; 1988, pp. 71-72.
94. Reitan RM, Wolfson, D. The Halstead-Reitan Neuropscyhological Test Battery: Theory and Clinical Interpretation 2nd ed. Tucson, Arizona: Neuropsychology Press, 1993.
95. White DA, Heaton RK, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:304-315
96. Miller EN, Wilkie FL. Computerized Testing to Assess Cognition in HIV-Positive Individuals, In Grant I, Martin A ed. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994, pp. 161-175
97. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21: 3557-3558
98. Miller EN, Satz P, Visscher B. Computerized and conventional neuropsychological assessment of HIV-1-infected homosexual men. Neurology. 41:1608-1616
99. Cull A, Hay C, Love SB, et al. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996;74:1674-1679
100. Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer. 2002;95:2017-2026
101. Poppelreuter M, Weis J, Kulz AK, et al. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer. 2004;40:43-49
102. Sbordone RJ. Limitations of neuropsychological testing to predict the cognitive and behavioral functioning of persons with brain injury in real-world settings. NeuroRehabilitation. 2001;16:199-201.
103. Radziwillllowicz W, Radziwillllowicz, P. Subjective and objective assessment of memory functions in endogenous depression. Arch Psych Psychother. 2000;2:33-41.
104. Vermeulen J, Aldenkamp AP, Alpherts WC. Memory complaints in epilepsy: Correlations with cognitive performance and neuroticism. Epilepsy Res. 1993;15:157-170
105. Vercoulen JH, Swanink CM, Galama JM, et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: Development of a model. J Psychosom Res. 1998;45:507-517
106. Sunderland A, Watts K, Baddeley AD, et al. Subjective memory assessment and test performance in elderly adults. J Gerontol. 1986;41:376-384
107. Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol. 2003;25:201-215
108. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317-331
109. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11:6-15.
110. Booth-Jones M, Jacobsen PB, Ransom S, et al. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005;36:695-702. (Pubitemid 41518712)
111. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs. 1999;22:185-94;quiz 195.
112. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2002;3(Suppl 3):S116-20.
113. Newman T, Browner WS, Hulley SB. Enhancing causal inference in observational studies, Designing clinical research:An epidemiologic approach 2nd ed. Philadelphia, Pa., Lippincott: Williams & Wilkins; 2000, pp. 125-138
114. Fletcher R, Fletcher SW, Wagner EH. Cause, in Satterfield T ed. Clinical Epidemiology 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1996, pp. 228-248
115. WinocurG,Vardy J,BinnsMA, et al.The effects of the anti-cancer drugs,methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006;85:66-75.
116. Lee GD, Longo DL, Wang Y, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res. 2006;12: 198-205.
117. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146-156
118. Saykin AJ, Ahles TA, Schoenfeld J.D. et al. Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsych Soc. 2003;9:246.
119. Booth CM, Vardy J, Crawley A, et al. Cognitive impairment associated with chemotherapy for breast cancer:An exploratory case-control study. J Clin Oncol (Meeting Abstracts). 2006;24:8501.
120. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303-311
121. Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001; 51:159-165
122. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional- dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer:An electrophysiologic study. Clin Breast Cancer. 2006;7:67-78.
123. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53-61.
124. Vezmar S, Becker A, Bode U, et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49:92-104.
125. Vardy J, Wong K, Yi QL, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14:1111-1118
126. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntington). 2000;14:151-161
127. Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19: 3385-3391
128. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.
129. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34:1670-1676
130. Knobf MT. Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol. 1986;4:678-684
131. Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11:971-975
132. Stone P, Ream E, Richardson A, et al. Cancer-related fatigue-a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. Eur J Cancer Care (Engl). 2003;12:20-27
133. Ashbury FD, Findlay H, Reynolds B, et al. A Canadian survey of cancer patients' experiences:Are their needs being met? J Pain Symptom Manage. 1998;16:298-306.
134. Stone P. The measurement, causes and effective management of cancer-related fatigue. Int J Palliat Nurs. 2002;8:120-128
135. Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16:1689-1696
136. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743-753
137. Jacobsen PB, Stein K. Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? Cancer Control. 1999;6:256-263
138. Richardson A. Fatigue in cancer patients:A review of the literature. Eur J Cancer Care (Engl). 1995;4:20-32.
139. Jacobsen PB. Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;93-97
140. Massie M. Depression, in Holland J, Rowland ed. Handbook of Psycho-oncology. New York: Oxford University Press; 1990, pp.283-290
141. Keating NL, Norredam M, Landrum MB, et al. Physical and mental health status of older long-term cancer survivors. J Am Geriatr Soc. 2005;53:2145-2152
142. Honda K, Goodwin RD. Cancer and mental disorders in a national community sample: Findings from the national comorbidity survey. Psychother Psychosom. 2004;73:235-242
143. Hewitt M, Rowland JH. Mental health service use among adult cancer survivors:Analyses of the National Health Interview Survey. J Clin Oncol 2002;20:4581-4590
144. Fallowfield L, Ratcliffe D, Jenkins V, et al. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer. 2001;84:1011-1015
145. Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751-757
146. Deimling GT, Kahana B, Bowman KF, et al. Cancer survivorship and psychological distress in later life. Psychooncology. 2002;11:479-494
147. Eberhardt B, Dilger S, Musial F, et al. Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol. 2006; 132:234-240
148. Eberhardt B, Dilger S, Musial F, et al. Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer. 2006;14:216-222
149. Tamoxifen for early breast cancer:An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467
150. Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364-371
151. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592-597
152. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802-1810
153. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959-2968
154. Yaffe K, Lui LY, Grady D, et al. Cognitive decline in women in relation to non-proteinbound oestradiol concentrations. Lancet. 2000;356:708-712
155. Barrett-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc. 1999;47:1289-1293 (Pubitemid 29523197)
156. Ciocca DR, Roig LM. Estrogen receptors in human nontarget tissues: Biological and clinical implications. Endocr Rev. 1995;16:35-62.
157. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study:A randomized controlled trial. JAMA. 2003;289:2663-2672
158. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165-176
159. Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients:A European survey. Ann Oncol. 2005;16:655-663 (Pubitemid 40613334)
160. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191-214.
161. Joseph JA, Denisova N, Fisher D, et al. Age-related neurodegeneration and oxidative stress: Putative nutritional intervention. Neurol Clin. 1998;16:747-755
162. Fillit HM, Butler RN, O'Connell AW, et al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc. 2002;77:681-696
163. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7:192-201.
164. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5:22.
165. Madhyastha S, Somayaji SN, Rao MS, et al. Hippocampal brain amines in methotrexate- induced learning and memory deficit. Can J Physiol Pharmacol. 2002;80:1076-1084
166. Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women:Reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184-4193
167. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage. 2004;28:7-18.
168. Mar Fan H, Yi Q-L, Park A, Braganza S, Chang J, Couture F, Tannock IF. The influence of erythropoietin on cognitive function in women following adjuvant chemotherapy for breast cancer. San Antonio Breast Cancer Symposium. San Antonio, Texas, 2004 Abstract No. 3075
169. Ramassamy C, Averill D, Beffert U, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999;27:544-553
170. Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: So if they don't divide what's to repair? Mutat Res. 2007;614:24-36.
171. Lee AY, Levine MN. Venous thromboembolism and cancer:Risks and outcomes. Circulation. 2003;107:I17-21.
172. Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer:Results from a randomized trial. Thromb Haemost. 1998;79:23-27
173. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation. 1998;98:196-199
174. Shea TB, Lyons-Weiler J, Rogers E. Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheimers Dis. 2002;4:261-267
175. Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol. 1999;19:314-316
176. Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status. Int J Cancer. 2002;98:84-91.
177. Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes. Neuroimmunomodulation. 2003;10: 319-327
178. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94-102.
179. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005; 104:788-793
180. Lee BN, Dantzer R, Langley KE, et al.Acytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11:279-292
181. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919-2925
182. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep. 2005;7:391-395
183. Scheibel RS, Valentine AD, O'Brien S, et al. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 2004;16:185-191
184. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999;461:75-81.
185. Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12:2759-2766
186. Vardy J, Booth C, Pond GR, Galica J, Zhang H, Dhillon H, Clarke SJ, Tannock IF. Cytokine levels in patients with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. American Society of Clinical Oncology. Chicago, 2007
187. Liberman JN, Stewart WF, Wesnes K, et al. Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. Neurology. 2002;58:1038-1044
188. Tardiff BE, Newman MF, Saunders AM, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg. 1997;64:715-720
189. Roses AD, Saunders AM. ApoE, Alzheimer's disease, and recovery from brain stress. Ann N Y Acad Sci. 1997; 826:200-212
190. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612-619
191. Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: The influence on risk and clinical outcome of haematological malignancies. Hematology. 2004;9:91-105. (Pubitemid 38697023)
192. Kreb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4-33.
193. Blasiak J, Arabski M, Krupa R, et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res. 2004;554: 139-148
194. Morley KI, Montgomery GW. The genetics of cognitive processes: Candidate genes in humans and animals. Behav Genet. 2001;31:511-531
195. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: Dopamine, COMT and BDNF. Genes Brain Behav. 2006;5:311-328
196. Schroder CP, Wisman GB, de Jong S, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer. 2001;84:1348-1353
197. Vasa-Nicotera M, Brouilette S, Mangino M, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet. 2005;76:147-151
198. Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001;19:1802-1808
199. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16:2522-2527
200. Mar Fan HG, Chemerenysky I, Xu W, Clemons M, Tannock IF. A randomised, placebo-controlled double-blind trial of the effects of d-methylphenidate therapy on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy, Canadian Breast Cancer Research Alliance Reasons for Hope 4th Scientific Conference. Montreal, 2006 Abstract M156.
201. Lower E, Fleishman S, Cooper A, et al.Aphase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and ''chemobrain'' in adult cancer patients. J Clin Oncol (Meeting Abstracts). 23:8000.
202. Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. 2000;11:230-237
203. Le Bars PL. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry. 2003;36(Suppl 1):S50-5.
204. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992;34:352-358
205. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev:CD003120. 2002.
206. Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000;152:353-361
207. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). 2000;151:416-423
208. Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharmacol Res. 1984;4:89-93
209. Birks J. Does donepezil improve well-being for dementia due to Alzheimer's disease? Neuroepidemiology. 2005;24:168-169
210. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev:CD005593. 2006.
211. Christodoulou C, Melville P, Scherl WF, et al. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci. 2006;245:127-136
212. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63:1579-1585
213. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 3:CD006104. 2006.
214. Eslinger PJ. Neuropsychological Interventions: Clinical Research and Practice. New York: Guilford Press; 2002.
215. Sohlberg MM, Mateer CA. Introduction to Cognitive Rehabilitation: Theory and Practice. New York: Guilford Press; 1989.
216. Sohlberg MM, Mateer CA. Cognitive Rehabilitation:An Integrative Neuropsychological Approach. New York: Guilford Press; 2001
217. Cicerone KD, Dahlberg C, Kalmar K, et al. Evidence-based cognitive rehabilitation:Recommendations for clinical practice. Arch Phys Med Rehabil. 2000;81:1596-1615
218. Carney N, Chesnut RM, Maynard H, et al. Effect of cognitive rehabilitation on outcomes for persons with traumatic brain injury:A systematic review. J Head Trauma Rehabil. 1999;14:277-307.
219. Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury. JAMA. 1999;282:974-983
220. Mateer CA, Sira CS, O'Connell ME. Putting Humpty Dumpty together again: The importance of integrating cognitive and emotional interventions. J Head Trauma Rehabil. 2005;20:62-75.
221. Sohlberg MM, McLaughlin KA, Pavese A, et al. Evaluation of attention process training and brain injury education in persons with acquired brain injury. J Clin Exp Neuropsychol. 2000;22:656-676
222. Cimprich B. Age and extent of surgery affect attention in women treated for breast cancer. Res Nurs Health. 1998;21:229-238
223. Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res. 2001;50:86-94.
224. Gottschalk LA, Holcombe RF, Jackson D, et al. The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol. 2003;25:117-122